Gilead and Merck's Weekly HIV Pill: A New Standard of Care Emerges

Key Takeaways

• Gilead and Merck's investigational once-weekly HIV treatment, islatravir/lenacapavir, achieved its primary efficacy endpoints in two Phase 3 trials, demonstrating non-inferiority to current daily therapies.
• The positive trial results, announced on 2026-07-21, signal a potential paradigm shift in HIV care, offering a convenient, long-acting oral option that could significantly improve patient adherence and reduce treatment-related stigma.
• With a comparable safety profile and a novel dual mechanism of action, this regimen positions both Gilead and Merck to capture a substantial share of the evolving HIV treatment market, driving future revenue growth.

A New Era for HIV Treatment: Weekly Dosing Breakthrough

The landscape of HIV treatment is on the cusp of a significant transformation, driven by the recent success of Gilead Sciences and Merck's experimental once-weekly oral pill, islatravir/lenacapavir. On July 21, 2026, the pharmaceutical giants announced that their combination regimen met its primary efficacy endpoints in two pivotal Phase 3 trials, ISLEND-1 and ISLEND-2. This breakthrough offers the promise of the first long-acting oral HIV treatment taken just once a week, a stark contrast to the daily regimens that have long been the standard.

This development is particularly critical for Gilead, a leader in HIV therapeutics, and Merck, which has been a key partner in the drug's development. Gilead Sciences (NASDAQ: GILD) currently trades at $130.56, commanding a market capitalization of $162.10 billion. Its shares have traded between a 52-week low of $108.06 and a high of $157.29, reflecting investor anticipation around its pipeline. Merck & Co., Inc. (NYSE: MRK), with a larger market cap of $311.67 billion and a current price of $126.19, also stands to benefit significantly. The ability to offer a less frequent dosing option addresses a critical unmet need, potentially enhancing patient quality of life and adherence, which are paramount in managing a chronic condition like HIV.

Efficacy and Safety: Non-Inferiority and a Clean Profile

The Phase 3 ISLEND trials were designed to rigorously evaluate the efficacy and safety of the once-weekly islatravir 2mg/lenacapavir 300mg (ISL/LEN) regimen. In ISLEND-1, the investigational pill was compared against Gilead's own BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide, B/F/TAF), a widely used daily single-tablet regimen, in virologically suppressed adults. The ISL/LEN combination proved to be statistically non-inferior to BIKTARVY, meeting the primary efficacy endpoint of maintaining HIV-1 RNA levels below 50 copies/mL at Week 48.

Similarly, the open-label ISLEND-2 trial demonstrated statistical non-inferiority when ISL/LEN was compared to a range of standard-of-care daily oral antiretroviral therapy regimens. Crucially, the safety profile observed for ISL/LEN was generally comparable to both BIKTARVY in ISLEND-1 and the various standard-of-care regimens in ISLEND-2, with no new safety concerns identified. This is a vital point, as earlier in 2021, the FDA had placed clinical holds on higher-dose islatravir studies due to observed decreases in total lymphocyte and CD4+ T-cell counts. The successful Phase 3 results with the lower 2mg dose of islatravir suggest these concerns have been effectively mitigated, paving the way for regulatory submissions.

The Mechanism Behind the Breakthrough: Islatravir and Lenacapavir

The potential of islatravir/lenacapavir stems from its innovative dual mechanism of action, combining two distinct classes of antiretrovirals. Islatravir, developed by Merck, is a nucleoside reverse transcriptase translocation inhibitor (NRTTI). It works by incorporating into nascent viral DNA, causing immediate or delayed chain termination and inducing structural changes that effectively halt HIV-1 replication. This mechanism provides high potency against both wild-type and drug-resistant HIV-1 strains, contributing to a high genetic barrier to resistance.

Gilead's lenacapavir, on the other hand, is a first-in-class capsid inhibitor. It disrupts the HIV lifecycle at multiple stages, including viral assembly, maturation, and uncoating. This multi-stage inhibition is distinguishable from other approved antiretroviral agents and exhibits no known cross-resistance with existing drug classes. The synergy between islatravir and lenacapavir, targeting the virus in different ways, is key to the regimen's efficacy and its potential to overcome resistance. As Dr. Elizabeth Rhee, Vice President, Global Clinical Development, Merck Research Laboratories, noted in October 2024, "Daily single-tablet regimens have helped to transform HIV care but can be challenging for some people to maintain. Novel HIV treatment options that allow for less frequent oral dosing have the potential to help support adherence, and address stigma faced by some individuals taking daily oral therapy." This combination directly addresses those challenges.

Market Opportunity: Addressing Unmet Needs and Expanding Reach

The introduction of a once-weekly oral HIV treatment could significantly reshape the HIV market. Current daily regimens, while highly effective, can pose adherence challenges for some individuals due to the daily pill burden and the psychological impact of taking medication every day. A weekly option offers unparalleled convenience, potentially leading to improved long-term viral suppression rates and better health outcomes for people living with HIV. This convenience also has the potential to reduce the stigma associated with daily medication, a factor that Dr. Jared Baeten, Vice President, HIV Clinical Development, Gilead Sciences, highlighted in March 2024: "HIV treatment is not one size fits all – developing once-weekly treatment options could help meet the needs of each individual, aiming toward maximizing long-term outcomes for people with HIV."

For Gilead and Merck, this translates into a substantial market opportunity. Gilead's HIV franchise is a cornerstone of its business, with its current daily BIKTARVY regimen being a market leader. The new weekly pill could either expand the overall market by improving adherence or allow the companies to capture share from other daily regimens. Analysts project Gilead's revenue to reach $38.7 billion by FY2030, with EPS of $13.13, while Merck's revenue is estimated at $74.0 billion by FY2030, with EPS of $9.81. These forward estimates likely incorporate the potential impact of pipeline successes like islatravir/lenacapavir, suggesting analysts are already factoring in significant growth from such innovations. The ability to offer a differentiated, long-acting oral option could solidify their positions and drive sustained revenue streams in the competitive HIV therapeutic space.

The Bear Case: Regulatory Hurdles and Competitive Landscape

Despite the overwhelmingly positive Phase 3 results, the path to market for islatravir/lenacapavir is not without its challenges. The companies plan to submit the Phase 3 data to regulatory authorities globally, but the approval process can be lengthy and unpredictable. Regulators will scrutinize the full dataset, including long-term safety and efficacy, especially given the prior clinical holds on islatravir. While the lower 2mg dose appears to have resolved the lymphocyte and CD4+ T-cell count issues, ongoing monitoring and post-market surveillance will be critical.

Furthermore, the HIV treatment landscape is dynamic and highly competitive. While islatravir/lenacapavir would be the first once-weekly oral option, other long-acting treatments are also in development, including injectable therapies. ViiV Healthcare, for instance, is advancing its own long-acting broadly neutralizing antibody (bNAb) lotivibart, with positive 12-month data from its Phase IIb EMBRACE trial presented at CROI 2026. These injectable options, while different in administration, also aim to reduce dosing frequency and improve adherence. The success of islatravir/lenacapavir will depend not only on its efficacy and safety but also on its ability to compete effectively against these emerging alternatives and secure favorable reimbursement. As Dr. Eliav Barr, Senior Vice President, Head of Global Clinical Development and Chief Medical Officer at Merck Research Laboratories, stated in June 2026, the goal is to "further expand options for people living with HIV," acknowledging the need to differentiate in a crowded market.

Analyst Outlook: Bullish on Innovation

Wall Street analysts have largely maintained a positive outlook on both Gilead and Merck, reflecting confidence in their robust pipelines and market positions. For Gilead (GILD), the consensus analyst rating is a Buy, with 40 out of 58 analysts recommending a Buy and 17 a Hold. The median price target stands at $162.50, implying a significant upside of 24.4% from its current price of $130.56. Recent rating changes, such as Morgan Stanley maintaining an Overweight rating on July 8, 2026, and Truist Securities maintaining a Buy rating on July 7, 2026, underscore this positive sentiment.

Merck (MRK) also enjoys a strong analyst consensus, with a Buy rating from 25 out of 37 analysts, and 11 recommending a Hold. The median price target for Merck is $142.00, suggesting a 12.5% upside from its current price of $126.19. BMO Capital and Guggenheim both maintained Buy/Outperform ratings on July 13, 2026. The positive Phase 3 results for islatravir/lenacapavir are likely to reinforce these bullish views, as the drug represents a significant potential revenue driver and a testament to both companies' commitment to innovation in a critical therapeutic area.

The Verdict: A New Standard of Care on the Horizon

The positive Phase 3 results for Gilead and Merck's once-weekly islatravir/lenacapavir regimen mark a pivotal moment in HIV treatment. This innovative oral therapy, offering a statistically non-inferior efficacy and comparable safety profile to daily standards, is poised to address long-standing challenges of adherence and stigma. The collaboration between two pharmaceutical powerhouses, combining a nucleoside reverse transcriptase translocation inhibitor with a first-in-class capsid inhibitor, creates a highly effective and differentiated treatment option. While regulatory approval and competitive pressures remain, the potential for this drug to become a new standard of care is substantial.

For investors, Gilead (GILD) appears particularly well-positioned to benefit from this breakthrough, given its deep roots in the HIV market and its role in developing lenacapavir. We anticipate that successful regulatory filings and a subsequent launch will drive Gilead's stock higher.

Entry Zone: Investors should consider accumulating GILD shares in the $128-$132 range, leveraging any short-term market fluctuations. 12-Month Target: Our 12-month price target for GILD is $165.00, reflecting the market's re-rating of its HIV franchise and the significant revenue potential of islatravir/lenacapavir. Invalidation Level: A sustained close below $118.00 would invalidate this thesis, suggesting unexpected regulatory setbacks or stronger-than-anticipated competitive headwinds.

The era of daily HIV pills may soon give way to a more convenient, patient-centric future, with Gilead and Merck leading the charge.

---

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.